Critical Outcome Technologies Inc. Strengthens Its Investor Relations Outreach

LONDON, ON -- (Marketwired) -- 04/02/15 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced today it has retained Stonegate Capital Partners, Inc. ("Stonegate") to provide strategic investor relations services on behalf of the Company in the United States with a specific focus on the U.S. small-cap life science institutional investment community. Stonegate is a Dallas-based consulting firm providing a full range of services to help a select group of public company clients build awareness, manage investor expectations, and broaden and strengthen investor relationships with a strong focus on institutional investors.

"With a broad range of services and extensive institutional investor relations and capital market experience, we expect that Stonegate will be a real asset to the Company in developing durable relationships with institutional investors," said Dr. Wayne Danter, President & Chief Executive Officer. "We have a great story to tell and have targeted early May for our initial company presentations to institutions in the U.S."

The agreement is for an initial six month term with the ability to terminate after three months upon ten days written notice, and if not terminated at that time then, any time after the initial six month period upon ten days written notice. Under the engagement, Stonegate receives a monthly consulting fee of $5,000 USD. The agreement is subject to the acceptance of the TSX Venture Exchange.

About Stonegate Capital Partners, Inc.

Stonegate Capital Partners is a privately owned investment banking and corporate advisory firm based in Dallas, TX dedicated to serving the specialized needs of small-cap public companies. For over 40 years, Stonegate has been bringing public companies and institutional investors together, either by virtue of private placements, coordinating block trades, or through open market transactions.

Since inception, Stonegate's mission has been to find innovative, undervalued public companies for its network of leading institutional investors who seek high quality investment opportunities. Its robust institutional outreach effort is the foundation of the firm, and a core aspect of its success. This, combined with their team's extensive institutional relationships and experience with complex capital market issues, creates an unparalleled platform for companies looking to grow their institutional shareholder base and ultimately realize optimal valuation in their stock. For further information, visit www.stonegateinc.com.

About Critical Outcome Technologies Inc.

COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI's proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

   For more information, visit www.criticaloutcome.com or contact: Critical Outcome Technologies Inc.Dr. Wayne DanterPresident & CEOTel: 519-858-5157Email: [email protected] CommunicationsTrevor HeislerInvestor Relations, CanadaTel: 416-500-8061Email: [email protected] Capital PartnersCasey StegmanInvestor Relations, United StatesTel: 972-850-2001Email: [email protected]

Source: Critical Outcome Technologies Inc. (COTI)

You May Also Be Interested In

• Storm Exploration Closes Non-Brokered Private Placement
• PlatON Unveils State-of-the-art Web3 Payment Solutions at Money 20/20 Asia
• Lantronix to Participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024